natgillin/translations-raw huggingface dataset:
The radiolabelled medicine is then given to the patient according to the instructions in that medicine’s summary of product characteristics (SmPC).
Radioaktivno označeno zdravilo se nato da bolniku v skladu z navodili iz povzetka glavnih značilnosti (SmPC) za to zdravilo.
The radiolabelled solution can be used for 6 hours when stored below 25°C.
Radiooznačena raztopina se lahko shranjuje 6 ur pri temperaturi do 25°C.
The radiolabelled solution is stable for 6 hours at 25°C.
Radiooznačena raztopina je stabilna 6 ur pri 25°C.
The radiolabelled solution should be administered intravenously as a single dose only.
Radioaktivno označena raztopina se uporabi intravensko kot en odmerek.
The radiologists did not know what treatment the patient had received beforehand, to make sure that the studies’ findings were as accurate as possible.
Da bi bili izsledki študije čim bolj natančni, radiologi niso vedeli, kakšno zdravljenje je bolnik pred tem prejel.
The radiomimetic action of thiotepa is believed to occur through the release of ethylene imine radicals that, as in the case of irradiation therapy, disrupt the bonds of DNA, e.g. by alkylation of guanine at the N-7, breaking the linkage between the purine base and the sugar and liberating alkylated guanine.
radiomimetičnega delovanja tiotepe naj bi prišlo zaradi sproščanja radikalov etilen imina, ki kot pri zdravljenju z obsevanjem prekine vezi DNK, npr. z alkilacijo gvanina na mestu N-7, kar prekine vez med purinsko bazo in sladkorjem ter sprosti alkiliran gvanin.
The radiopharmaceutical for the myocardial perfusion imaging agent should be administered 10-20 seconds after the sodium chloride 9 mg/ml (0.9%) solution for injection.
Radiofarmacevtski izdelek za zdravilo, ki se uporablja za slikanje miokardne perfuzije je treba dati 10- 20 sekund po 0,9% (9 mg/ml) raztopini natrijevega klorida za injiciranje.
The radiopharmaceutical for the myocardial perfusion imaging agent should be administered 10-20 seconds after the sodium chloride 9 mg/ml (0.9%) solution for injection.
Radiofarmacevtski izdelek za zdravilo, ki se uporablja za slikanje miokardne perfuzije je treba dati 10-20 sekund po 0,9% (9 mg/ml) raztopini natrijevega klorida za injiciranje.
The radiopharmaceutical precursor solution is packaged in colourless type I glass vial of 10 mL, closed with a bromobutylrubber stopper and aluminium overseal.
Raztopina radionuklidnega predhodnika je pakirana v brezbarvno vialo iz stekla tipa I in s prostornino 10 ml, ki je zaprta z zaporko iz bromobutilne gume in z aluminijastim pokrovčkom.
The radiopharmaceutical precursor solution is packaged in colourless, type I glass 10 mL vial, closed with bromobutyl rubber stopper and aluminium overseal.
Raztopina radiofarmacevtskega predhodnika je pakirana v brezbarvno stekleno (tip I) vialo s prostornino 10 ml, zaprto z zamaškom iz bromobutilne gume in aluminijasto zaščitno zaporko.
The raised dots can be felt even when the blister is already inserted for reassurance that the correct dose is used.
Izbokline lahko otipate, tudi ko je pretisni omot že vstavljen, in se tako prepričate, da ste uporabili pravilni odmerek.
The Rapamune dose should then be individualised to obtain whole blood trough levels of 4 to 12 ng/mL (chromatographic assay).
Odmerek zdravila Rapamune je treba nato individualno prilagoditi tako, da so najnižje koncentracije učinkovine v stanju dinamičnega ravnovesja v polni krvi med 4 in 12 ng/ml (kromatografska metoda).
The Rapamune group failed to demonstrate superiority to the control group in terms of the first occurrence of biopsy confirmed acute rejection, graft loss, or death.
Glede prvega pojava akutne zavrnitve presadka, potrjene z biopsijo, izgube presadka ali smrti se skupina z zdravilom Rapamune ni izkazala za boljšo v primerjavi s kontrolno skupino.
The rape utic indications
Terape vtske indikacije
The rape uticindications
Terapevtske indikacije
The rapeuticindications
Terapevtske indikacije
The rapid onset and early peak of activity of insulin lispro is observed following the subcutaneous administration of Humalog Mix25.
Po subkutanem injiciranju zdravila Humalog Mix25 začne insulin lispro delovati hitro in zgodaj doseže vrh delovanja.
The rapid onset and early peak of activity of insulin lispro is observed following the subcutaneous administration of Humalog Mix50.
Po subkutanem injiciranju zdravila Humalog Mix50 začne insulin lispro delovati hitro in zgodaj doseže vrh delovanja.
The rapid onset and early peak of activity of insulin lispro is observed following the subcutaneous administration of Liprolog Mix50.
Po subkutanem injiciranju zdravila Liprolog Mix50 začne insulin lispro delovati hitro in zgodaj doseže vrh delovanja.
The rapid schedule was tested for concomitant administration of IXIARO and Rabipur but it can also be used for administration of IXIARO alone, as no immune interference of the two vaccines has been observed (see section 4.5).
Hitri urnik je bil preizkušen za hkratno odmerjanje cepiv IXIARO in Rabipur, lahko pa ga uporabimo tudi zgolj za odmerjanje cepiva IXIARO, saj niso bile opažene nobene motnje imunskega odziva na obe cepivi (glejte poglavje 4.5).
The Raplixa spray device comes with the rigid nozzle attached.
Pripomoček RaplixaSpray ima priključeno togo šobo.
The Raplixa spray device is connected to the ProFibrix pressure regulator and thereby to the medical gas supply set to a pressure setting of 1.5 bar (22 psi).
Pripomoček RaplixaSpray se poveže z regulatorjem tlaka ProFibrix in s tem z dovajanjem medicinskega zraka, nastavljenim na tlak 1,5 bara (22 psi).
The Raplixa spray device is used to spray the powder on to the bleeding site and then the gelatin sheet is applied (see Instructions For Use for Raplixa spray device and gelatin sponge).
Pripomoček RaplixaSpray se uporablja za pršenje praška na mesto krvavitve, nato pa se nanese želatinska gobica (glejte navodilo za uporabo pripomočka RaplixaSpray in želatinske gobice).
The rapporteur acknowledges that these results may vary with the final analysis.
Poročevalec priznava, da bodo morda ti rezultati pri končni analizi drugačni.
The RAS mutant population consists of patients with known KRAS exon 2 mutations as well as additionally identified RAS mutations.
Populacija z mutacijo RAS je sestavljena iz bolnikov z znanimi mutacijami na eksonu 2 gena KRAS in z dodatno opredeljenimi mutacijami RAS.
The rash may progress to widespread blistering or peeling of the skin and may be life-threatening.
Izpuščaj lahko napreduje do obširnih mehurjev na koži in luščenja kože in je lahko življenjsko nevaren.
The rate (95% confidence interval) of lymphomas was 1.0 (0.2, 3.8) per 1000 patient-years among Trudexa-treated patients and 1.0 (0.1, 7.3) per 1000 patient- years among control patients.
Delež (95% interval zaupanja) limfomov je bil 1,0 (0,2, 3,8) na 1000 bolnik-let med bolniki, ki so dobivali Trudexo, in 1,0 (0,1, 7,3) na 1000 bolnik-let v kontrolni skupini bolnikov.
The rate (95% confidence interval) of non-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000 patient-years among Humira-treated patients and 3.2 (1.3, 7.6) per 1,000 patient-years among control patients.
Delež (95 % interval zaupanja) nemelanomskih kožnih rakov je bil 8,8 (6,0; 13,0) na 1000 bolnikov- let med bolniki, ki so dobivali zdravilo Humira, in 3,2 (1,3; 7,6) na 1000 bolnikov-let med kontrolnimi bolniki.
The rate and extent of absorption of metformin from Eucreas 50 mg/1000 mg were decreased when given with food as reflected by the decrease in Cmax by 26%, AUC by 7% and delayed Tmax (2.0 to 4.0 h).
Hitrost in obseg absorpcije metformina iz zdravila Eucreas 50 mg/1000 mg pa sta bili pri jemanju s hrano zmanjšani, kar se je odražalo na znižanju Cmax za 26 %, zmanjšanju AUC za 7 % in na podaljšanem Tmax (2,0 do 4,0 ure).
The rate and extent of absorption of Onduarp are equivalent to the bioavailability of telmisartan and amlodipine when administered as individual tablets.
Hitrost in obseg absorpcije zdravila Onduarp sta enakovredna biološki uporabnosti telmisartana in amlodipina, kadar jih bolniki jemljejo kot posamični zdravili.
The rate and extent of absorption of tadalafil are not influenced by food, thus tadalafil may be taken with or without food.
Ker hrana ne vpliva na stopnjo in obseg absorpcije tadalafila, se lahko zdravilo Tadalafil Mylan vzame s hrano ali brez nje.
The rate and extent of absorption of teduglutide is dose-proportional at single and repeated subcutaneous doses up to 20 mg.
Hitrost in stopnja absorpcije teduglutida sta sorazmerni z velikostjo odmerka pri enkratnem odmerku in pri ponovljenih subkutanih odmerkih do20 mg.
The rate and extent of sirolimus absorption was significantly increased by ciclosporin A (CsA).
Ciklosporin A (CsA) močno zveča hitrost in obseg absorpcije sirolimusa.
The rate at which the dose of sirolimus is increased should correspond to the rate of ciclosporin elimination.
Hitrost, s katero se zvečuje odmerek sirolimusa, naj ustreza hitrosti zmanjševanja odmerka oziroma ukinitve ciklosporina.
The rate of administration should be determined by the patient’s comfort level (maximal rate of infusion: 2 ml/min).
Hitrost injiciranja naj bo prilagojena bolnikovemu počutju (največja dovoljena hitrost injiciranja je 2 ml/min).
The rate of administration should be determined by the patient’s comfort level (maximal rate of infusion: 2 mL/min).
Hitrost injiciranja naj bo prilagojena bolnikovemu počutju (največja dovoljena hitrost injiciranja: 2 ml/min).
The rate of administration should be determined by the patient’s comfort level (maximal rate of infusion: 2 ml/min).
Hitrost injiciranja naj bo prilagojena počutju bolnika (največja hitrost injiciranja je 2 ml/min).
The rate of administration should be determined by the patient’s comfort level (maximal rate of infusion: mL/min).
Hitrost injiciranja naj bo prilagojena bolnikovemu počutju (največja dovoljena hitrost injiciranja je 2 ml/min).
The rate of administration should be determined by the patient’s comfort level and should not exceed 10 mL/min.
Hitrost dajanja se določi glede na raven bolnikovega udobja in ne sme preseči 10 ml/min.
The rate of administration should be determined by the patient’s comfort level, up to a maximum of 5 ml/min.
Hitrost dajanja je treba določiti na podlagi bolnikovega počutja, in sicer do največ 5 ml/min.
The rate of administration should be determined by the patient’s comfort level.
Hitrost dajanja zdravila je treba prilagoditi bolnikovemu počutju.
The rate of administration should be determined by the patient’s comfort level.
Hitrost injiciranja je odvisna od bolnikovega počutja.
The rate of ARRs of all grades varied between studies depending on the indication, the data collection methodology, and whether trastuzumab was given concurrently with chemotherapy or as monotherapy.
Pogostnost reakcij, povezanih z aplikacijo vseh stopenj, je bila različna po študijah glede na indikacijo, metodologijo zbiranja podatkov in glede na to, ali so trastuzumab dajali sočasno s kemoterapijo ali v monoterapiji.
The rate of atrial fibrillation serious adverse events was 1.3% (51 out of 3,862) and 0.6% (22 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively.
Delež atrijske fibrilacije, ki so jo opredelili kot resen neželen dogodek, je bil pri bolnicah, ki so prejemale 5 mg zoledronske kisline, 1,3 % (pri 51 od 3.862 bolnic), pri bolnicah, ki so prejemale placebo, pa 0,6 % (pri 22 od
The rate of atrial fibrillation serious adverse events was 1.3% (51 out of 3,862) and 0.6% (22 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively.
Delež atrijske fibrilacije, ki so jo opredelili kot resen neželen dogodek, je bil pri bolnicah, ki so prejemale 5 mg zoledronske kisline, 1,3% (pri 51 od 3.862 bolnic), pri bolnicah, ki so prejemale placebo, pa 0,6% (pri 22 od 3.852 bolnic).
The rate of clearance of the active metabolite, corrected for body- weight, decreases with ages below one year.
Stopnja očistka aktivnega presnovka, korigiranega za telesno maso, se zmanjšuje s starostjo pod 1 letom.
The rate of clearance of the active metabolite, corrected for body-weight, decreases with ages below one year.
Stopnja očistka aktivnega presnovka, korigiranega za telesno maso, se zmanjšuje s starostjo pod 1 letom.
The rate of death in the sirolimus conversion group was higher than the CNI continuation group, although the rates were not significantly different.
Smrtnost v skupini s prehodom na sirolimus je bila večja kot v skupini, ki je nadaljevala s CNI, čeprav razlika ni bila statistično pomembna.
The rate of documented symptomatic hypoglycaemia with Trulicity 1.5 mg and 0.75 mg, and metformin were 0.62, 0.15, and 0.09 episodes/patient/year, respectively.
Stopnja dokumentirane simptomatske hipoglikemije za zdravilo Trulicity 1,5 mg in 0,75 mg in sitagliptin je bila 0,19, 0,18, in 0,17 epizod/bolnika/leto.
The rate of fever equal to or greater than 40 °C increased after booster immunisation but remained
Stopnja pojavnosti vročine  40 °C je povečana pri poživitvenem cepljenju, vendar ostaja pod 1 %.
The rate of grade 3 (severe) reactions was overall low (≤ 2%).
Pojav reakcij 3. stopnje (hude) reakcije je bil v splošnem majhen (≤ 2 %).
The rate of haematological response was 70 % with a duration of 2–3 months.
Stopnja hematološkega odziva je bila 70 %, njegovo trajanje pa 2–3 mesece.
The rate of haematological response was 70% with a duration of 2-3 months.
Stopnja hematološkega odziva je bila 70 %, njegovo trajanje pa 2–3 mesece.
The rate of haematological response was 70% with a duration of 2–3 months.
Stopnja hematološkega odziva je bila 70 %, njegovo trajanje pa 2–3 mesece.
The rate of hepatocellular carcinoma was 18% (8/45) in the tenofovir disoproxil fumarate group, 7% (3/45) in the emtricitabine plus tenofovir disoproxil fumarate group and 9% (2/22) in the entecavir group.
Stopnja hepatoceličnega karcinoma je bila 18% (8/45) v skupini z dizoproksiltenofovirijevim fumaratom, 7% (3/45) v skupini z emtricitabinom in dizoproksiltenofovirijevim fumaratom in 9% (2/22) v skupini z entekavirjem.
The rate of herpes zoster was slightly higher in PV (6.4%) patients than in MF (4.0%) patients.
Pogostnost herpesa zostra je bila nekoliko večja pri bolnikih s pravo policitemijo (6,4 %) kot pri bolnikih z mielofibrozo (4,0 %).
The rate of increase in haemoglobin should be approximately 1 g/dl (0.62 mmol/l) per month and should not exceed 2 g/dl (1.25 mmol/l) per month to minimize the risk of developing or worsening of hypertension.
Hitrost, s katero se dviga hemoglobin, naj bi bila približno 1g/dl (0,62 mmol/l) na mesec in naj ne bi presegala 2g/dl (1,25 mmol/l) na mesec, da se zmanjša tveganje za razvoj ali poslabšanje hipertenzije.
The rate of infection was 0.91 per patient-year of follow-up in ustekinumab-treated patients, and the rate of serious infections was 0.02 per patient-year of follow-up in ustekinumab-treated patients (178 serious infections in 10,953 patient-years of follow-up) and serious infections reported included anal abscess, cellulitis, pneumonia, diverticulitis, gastroenteritis and viral infections.
Pogostnost okužb je bila 0,86 na bolnikov-let spremljanja za bolnike, zdravljene z ustekinumabom, pogostnost resnih okužb pa je znašala 0,01 na bolnikov-let spremljanja tudi za bolnike, zdravljene z ustekinumabom (107 resnih okužb na 9.848 bolnikov-let spremljanja) in med poročane resne okužbe so sodili divertikulitis, celulitis, pljučnica, sepsa, apendicitis in holecistitis.
The rate of infusion can be escalated in increments of 50 mg/hr every 30 minutes to a maximum rate of 400 mg/hr.
Hitrost infundiranja je mogoče povečevati v korakih po 50 mg/uro vsakih 30 minut do največje hitrosti 400 mg/uro.
The rate of infusion was
Hitrost infuzije pri bolnikih s serumskim kreatininom
The rate of MMR at 12 months, was also statistically significantly higher for nilotinib 400 mg twice daily compared to imatinib 400 mg once daily (42.7% versus 22.3%, p<0.0001).
12 mesecih je bil statistično značilno večji tudi pri bolnikih, ki so prejemali nilotinib 400 mg dvakrat dnevno v primerjavi s tistimi, ki so prejemali imatinib 400 mg enkrat dnevno (42,7 % v primerjavi z 22,3 %, p<0,0001).
The rate of pregabalin absorption is decreased when given with food resulting in a decrease in Cmax by approximately 25 – 30% and a delay in tmax to approximately 2.5 hours.
Hitrost absorpcije pregabalina se zmanjša, če je uporabljen s hrano; Cmax se zmanjša za približno 25–30 % in tmax se podaljša na približno 2,5 ure.
The rate of pregabalin absorption is decreased when given with food resulting in a decrease in Cmax by approximately 25-30% and a delay in tmax to approximately 2.5 hours.
Hitrost absorpcije pregabalina se zmanjša, če je uporabljen s hrano; Cmax se zmanjša za približno 25–30 % in Tmax se podaljša na približno 2,5 ure.
The rate of progression of structural damage in year 2 was significantly lower than that in year 1 for patients randomized to abatacept (p < 0.0001).
Pri bolnikih, ki so bili randomizirani na abatacept, je bil obseg napredovanja strukturnih poškodb v drugem letu pomembno manjši kot v prvem letu (p < 0,0001).
The rate of progression to squamous cell carcinoma (SCC) was reported in 1.6% (2/128 patients).
Poročali so, da je stopnja rasti skvamozno celičnega SCC pri 1,6%(2/128) bolnikih.
The rate of responders (either a reduction in serum phosphorus ≤ 1.78 mmol/L and/or a reduction from baseline ≥ 0.3 mmol/L) was 50.4 % and 43.8% in the two studies, respectively (placebo 30.8% and 26.3%, respectively).
Primerjava deležev bolnikov, ki so se odzvali na zdravljenje (z znižanjem plazemskega fosforja ≤ 1,78 mmol/l in/ali z znižanjem od izhodiščne vrednosti ≥ 0,3 mmol/l) je bila v dveh študijah 50,4 % in 43,8 % (v primerjavi s placebom 30,8 % in 26,3 %).
The rate of serious cardiac events was 2.1 per 100 patient years (95% CI 3
Delež resnih srčnih dogodkov je bil 2,1 na 100 bolnik- let (95-% interval zaupanja, 3–15).
The rate of serious infections was numerically higher in patients weighing <30 kg treated with 10 mg/kg tocilizumab (12.2 per 100 patient years) compared to patients weighing ≥30 kg, treated with 8 mg/kg tocilizumab (4.0 per 100 patient years).
Delež resnih okužb je bil številčno večji pri bolnikih s telesno maso < 30 kg, ki so se zdravili z 10 mg/kg tocilizumaba (12,2 na 100 bolnik-let) v primerjavi z bolniki s telesno maso ≥ 30 kg, ki so se zdravili z 8 mg/kg tocilizumaba (4,0 na 100 bolnik-let).
The rate of the 30-day composite endpoint of death, myocardial re-infarction or intracranial haemorrhage (a measure of net clinical benefit) was significantly lower (p < 0.0001) in the enoxaparin group (10.1%) as compared to the heparin group (12.2%), representing a 17% relative risk reduction in favour of treatment with enoxaparin sodium.
Delež smrti, ponovnega miokardnega infarkta ali intrakranialne krvavitve (mera neto klinične koristi) kot sestavljenega izida v 30 dneh je bil v skupini z enoksaparinom značilno manjši (10,1 %) kot v skupini s heparinom (12,2 %) (p < 0,0001), kar pomeni 17-odstotno zmanjšanje relativnega tveganja v prid zdravljenju z natrijevim enoksaparinatom.
The rate of the combination of MBEs/CRBEs and the rate of any bleeding was significantly lower at a nominal alpha level of 5 % in patients receiving placebo as compared with those receiving dabigatran etexilate.
Stopnja kombinacije velikih krvavitev/klinično pomembnih krvavitev in stopnja vseh krvavitev je bila na 5-odstotni nominalni ravni alfa značilno nižja pri bolnikih, ki so prejemali placebo, kot pri zdravljenih z dabigatran eteksilatom.
The rate of the infusion can be escalated in increments of 50 mg/hr every 30 minutes to a maximum rate of 400 mg/hr.
Hitrost infundiranja je mogoče povečevati v korakih po 50 mg/uro vsakih 30 minut do največje hitrosti 400 mg/uro.
The rate of TKV increase over 3 years was significantly less for tolvaptan-treated subjects than for subjects receiving placebo: 2.80% per year vs 5.51% per year, respectively (ratio of geometric mean 0.974; 95% CI 0.969 to 0.980; p < 0.0001).
Stopnja povečanja TKV v 3 letih je bila značilno manjša pri osebah, zdravljenih s tolvaptanom, v primerjavi z osebami, ki so prejemale placebo: 2,80 % na leto v primerjavi s 5,51 % na leto (razmerje geometričnega povprečja 0,974; 95-% IZ 0,969 do 0,980; p < 0,0001).
The rate of withdrawal due to adverse events was higher in the XELOX combination therapy arm (21%) as compared with that of the 5-FU/LV monotherapy arm (9%) in the ITT population.
Delež prekinitev zdravljenja zaradi neželenih učinkov je bil v populaciji, ki so jo nameravali zdraviti (ITT), v skupini s shemo kombiniranega zdravljenja XELOX višji (21 %) v primerjavi s skupino z monoterapijo s 5- FU/LV (9 %).
The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.00 (0 patients out of 278) for Xultophy and 0.01 (1 patient out of 279) for insulin glargine.
Delež hude hipoglikemije na bolnikov-let izpostavljenosti (odstotek bolnikov) je bil pri zdravilu Xultophy 0,00 (0 od 278 bolnikov), pri insulinu glargin pa 0,01 (1 od 279 bolnikov).
The rate should be determined by the patient’s comfort level.
Hitrost je treba določiti glede na bolnikovo počutje.
The rates (events per patient year of exposure) of severe hypoglycaemia (ISPAD definition; 0.51 vs 0.33), confirmed hypoglycaemia (57.71 vs 54.05) and nocturnal confirmed hypoglycaemia (6.03 vs 7.60) were comparable with Tresiba versus insulin detemir.
Pri zdravilu Tresiba so bili deleži (dogodki na bolnik-let izpostavljenosti) hude hipoglikemije (opredelitev po ISPAD; 0,51 v primerjavi z 0,33), potrjene hipoglikemije (57,71 v primerjavi s 54,05) in potrjene nočne hipoglikemije (6,03 v primerjavi s 7,60) primerljivi z insulinom detemir.
The rates (events per patient-year of exposure) of confirmed hypoglycaemia (ISPAD 2009 definition: 46.23 vs 49.55) and nocturnal confirmed hypoglycaemia (5.77 vs 5.40) were comparable with Ryzodeg versus insulin detemir whereas the rate of severe hypoglycaemia (0.26 vs 0.07) was higher in the Ryzodeg arm although the difference was not statistically significant.
Deleži (dogodki na bolnik-let izpostavljenosti) potrjene hipoglikemije (opredelitev po ISPAD 2009: 46,23 v primerjavi z 49,55) in potrjene nočne hipoglikemije (5,77 v primerjavi s 5,40) so bili pri zdravilu Ryzodeg primerljivi z deleži pri insulinu detemir, delež hude hipoglikemije pa je bil v skupini z zdravilom Ryzodeg večji (0,26 v primerjavi z 0,07), čeprav razlika ni bila statistično značilna.
The rates for congenital malformations (major and minor combined) reported for infants born after an FTET cycle (16.4%) were similar to those reported for infants born after fresh ART cycles (19.5%).
Delež prirojenih malformacij (manjših in večjih skupaj) pri otrocih, rojenih po FTET ciklu (16,4 %), je bil podoben deležu pri otrocih, rojenih po ART ciklu s svežimi zarodki (19,5 %).
The rates of acute rejection, graft loss, and death were similar at 1 and 2 years.
Pogostnost akutne zavrnitve, izgube presadka in smrti je bila po 1 letu in 2 letih podobna.
The rates of acute rejection, graft loss, and death were similar at 1 and 2 years.
Pogostnosti akutne zavrnitve, izgube presadka in smrti je bila po 1 letu in 2 letih podobna.
The rates of acute rejection, graft loss, and death were similar, but urinary protein excretion was increased in the Rapamune treatment arm of this subset.
Pogostnost akutne zavrnitve, izgube presadka in smrti je bila podobna, izločanje beljakovin z urinom pa se je v tistem kraku te podskupine, ki je prejemal zdravilo Rapamune, zvečalo.
The rates of adverse reactions leading to permanent treatment discontinuation were 11% for the ONIVYDE+5-FU/LV arm and 12% for the monotherapy arm.
Delež neželenih učinkov, zaradi katerih je prišlo do dokončne prekinitve zdravljenja, je bil 11 % v veji z zdravilom ONIVYDE+5-FU/LV in 12 % v veji z monoterapijo.
The rates of cCCyR in the SPRYCEL and imatinib treatment groups, respectively, within 3 months (54% and 30%), 6 months (70% and 56%), 9 months (75% and 63%), 24 months (80% and 74%),
Deleži cCCyR v skupini, ki je prejemala zdravilo SPRYCEL in v skupini, ki je prejemala imatinib, so bili v 3 mesecih (54% oziroma 30%), 6 mesecih (70% oziroma 56%), 9 mesecih (75% oziroma 63%),